Articles tagged with Pancreatic Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A study found that socioeconomic factors like race, ethnicity, insurance status, and geographic location affect the likelihood of undergoing surgery for early-stage pancreatic cancer. Patients who underwent resection had improved disease-specific survival compared to those who did not, with regional differences in survival rates observed.
Researchers at IUPUI developed a nanotech-based sensor to detect microRNAs in blood, enabling early cancer diagnosis and potentially improving treatment outcomes. The sensor's ultrasensitivity allows for the detection of minute changes in microRNA concentrations.
A new study developed a potential test to sort out precancerous pancreatic cysts from harmless ones, with an accuracy rate of up to 98 percent. The test combines genetic markers and clinical evaluation, potentially helping patients avoid unnecessary surgery.
Researchers discovered peptides that inhibit metastatic spreading and even lead to regression of existing metastases in pancreatic cancer models. The CD44v6 protein drives the spread of tumor cells, but small segments of the protein can be successfully inhibited by peptides.
Researchers are developing new technologies to analyze pancreatic tumor super-enhancers and testing therapies targeting these signals in clinical trials. The goal is to reprogram cancer cells or create vulnerabilities that can be exploited with combination drug therapies.
A team of top researchers will focus on reprogramming pancreatic tumor biology using cutting-edge technology and developing new SE-targeted drugs. The goal is to dial up sensitivity to chemotherapy and push tumors into lasting remission.
A team of top researchers, led by TGen's Dr. Daniel D. Von Hoff, aims to develop therapies that greatly improve patient survival. They will focus on reprogramming the 'super enhancers' in cancer cells to stop tumor growth and offer novel treatments for patients with pancreatic cancer.
A recent study by Mayo Clinic reveals that only one in five US pancreatic cancer patients receive the CA 19-9 tumor marker test at diagnosis, which can help predict treatment outcomes and guide personalized treatment. The test eliminates negative effects on survival when chemotherapy is administered before surgery.
A new study by Fred Hutchinson Cancer Center researchers found that immunotherapy can boost survival from pancreatic cancer by more than 75% in mice, even without chemotherapy or radiation. The therapy targets mesothelin, a protein overproduced by virtually all pancreatic tumors.
Researchers have discovered a genomic molecular fingerprint, signature 3, that highlights certain gastric cancers susceptible to treatment with platinum drugs or PARP inhibitor drugs. This biomarker could guide targeted therapy for breast, ovarian and pancreatic cancers as well.
New data from clinical trials at Penn Medicine demonstrate the clinical benefits of proton therapy for patients with advanced lung, pancreatic, and spine cancers. Proton therapy has been shown to reduce toxicities and improve survival rates compared to conventional radiation therapy.
UT Southwestern researchers have developed a classification model for cancers caused by KRAS, the most frequently mutated gene in cancer. The model helps predict the propensity of different KRAS mutants to signal through RAF kinase and could lead to more effective targeted therapies.
A Binghamton University biochemist has discovered a method to fight cancer by attacking only cancer cells and potentially reducing side effects. Hedgehogs, which normally turn off in mature cells, somehow re-activate in certain cancers, leading to uncontrolled cell growth.
Researchers have found that a protein called FAK plays a key role in the development of pancreatic neuroendocrine tumors. A two-drug combination has been shown to be more effective than everolimus alone in killing cancer cells and reducing tumor volume.
A combination of two drugs has been found to shrink pancreatic tumors in laboratory mice. The treatment, which targets the cell's DNA rather than proteins, also slowed the growth of human lung cancer cells. Researchers are now working to test this treatment in humans with pancreatic cancer.
A five-year programme will focus on developing miniscule technology to deliver drugs directly to cancer sites, improving chemotherapy effectiveness. The project tackles an important area around drug delivery in pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.
Researchers have discovered that an anti-diabetic drug can 'suffocate' pancreatic cancer stem cells by preventing them from using oxygen for energy. This finding holds promise for developing new treatments that target these cancer stem cells and prevent recurrence after conventional treatment. Pancreatic cancer remains one of the most ...
Researchers at H. Lee Moffitt Cancer Center are developing a blood test using microRNAs to identify and characterize precursor lesions that can progress to pancreatic cancer. The test may help differentiate between low- and high-risk lesions, allowing for more informed personalized medical management decisions.
University of Houston researchers identify liver X receptors as a promising target for developing new pancreatic cancer treatments. The study, led by Chin-Yo Lin, shows that targeting these receptors can slow the growth of tumors and is expected to lead to the development of new drugs.
A study found genes associated with improved survival after surgery for pancreatic cancer patients. Detection of circulating tumor DNA in the blood predicted clinical relapse and poor outcomes.
Scientists at Johns Hopkins Medicine identified a molecular partnership between annexin A2 and Sema3D that helps explain how pancreatic cancer spreads. Annexin A2, already linked to poor survival rates, guides the release of Sema3D, which fuels the cancer's spread by tracking nerve cells.
Researchers at Barts Cancer Institute have identified a three-protein 'signature' in urine that can accurately detect early-stage pancreatic cancer with over 90% accuracy. This discovery could lead to a simple and inexpensive test for high-risk individuals, improving survival rates.
Researchers found no statistically significant association between pioglitazone use and bladder cancer risk. However, a small increased risk was observed, as well as associations with increased prostate and pancreatic cancer risks.
A recent genome-sequencing study discovered at least one-third of patients' tumors have genetic mutations that can guide precision therapy. Blood tests detecting DNA shed from tumors predicted cancer recurrence more than half a year earlier than standard imaging methods.
Indiana University researchers found that restoring missing microRNA-29 in pancreatic cancer stromal cells reduced the viability and growth of cancerous cells. The study suggests that miR-29 could be a potent therapeutic agent against pancreatic cancer by targeting reactive tumor stroma.
Scientists at University College London have designed a chemical compound called MM41 that targets quadruplexes, faulty genes found in pancreatic cancers. The compound reduced tumor growth by 80% and prevented regrowth in mice, showing promise for treating pancreatic cancer.
Researchers at MD Anderson Cancer Center have identified a potential non-invasive diagnostic tool for early pancreatic cancer detection. Glypican-1-enriched circulating exosomes were found to be present in small amounts of serum from patients with pancreatic cancer, showing high specificity and sensitivity. Early detection of pancreati...
Researchers have uncovered four regions in the human genome where changes may increase pancreatic cancer risk, with specific variants linked to a 38% increased risk at position 17q25.1. The study confirms connections between pancreatic cancer risk and genetic variants linked to other cancers.
Leading researchers from Canada and Israel are working together to uncover the molecular landscape of pancreatic cancer and develop new biomarkers for detection and diagnostics. The collaboration aims to improve patient outcomes by discovering targeted therapies.
A systematic review and meta-analysis of 36 observational studies found that nut consumption is associated with a decreased risk of colorectal cancer, endometrial cancer, and pancreatic cancer. However, it was not linked to type 2 diabetes.
Researchers at VCU Massey Cancer Center have found a promising combination of an experimental drug and common antibiotic Minocycline to target pancreatic cancer cells. The synergistic effect of the two drugs eliminated Stat3 expression, a key protein regulating tumor growth.
Researchers found that stereotactic body radiation therapy (SBRT) is safe and as effective as standard radiation treatment for certain patients with locally advanced pancreatic cancer. SBRT delivers high doses of radiation in a short period, resulting in reduced pain and improved quality of life. The treatment also allowed some patient...
A study published in Nature Cell Biology reveals that exosomes secreted by pancreatic cancer cells contain MIF, which educates liver cells to produce a protein leading to fibrosis and tumor growth. This discovery could lead to targeted treatments and biomarkers for early detection.
Researchers at UC San Diego found that pancreatic cancer rates are highest in countries with the least amount of sunlight, due to low vitamin D levels. Limited foods naturally contain vitamin D, and experts suggest that a deficiency may contribute to an increased risk of pancreatic cancer.
Despite recent advances in understanding pancreatic cancer biology, researchers have made little progress in finding effective treatments. However, a new review suggests that immunotherapy combined with other treatments may significantly increase patient survival rates, and could lead to new therapeutic strategies.
Researchers have discovered a way to make pancreatic cancer cells more susceptible to oncolytic viruses by exploiting the communication between cancer cells and supportive cells, such as cancer-associated fibroblasts. This weakness can be exploited to improve treatment outcomes for patients with pancreatic cancer.
Researchers identify ways to improve recruitment and efficiency of IMPaCT trial, a personalized pancreas cancer clinical trial that used genomic sequencing to guide treatment. The trial showed promise despite initial challenges, including slow technology adoption and complex administrative processes.
DECT imaging enhances pancreatic cancer assessment through improved lesion detection and characterization, potentially improving patient outcomes. The technique has shown promise in detecting and evaluating pancreatic tumors, offering a more comprehensive analysis than traditional single-energy CT imaging.
Researchers have identified a novel approach to treating pancreatic cancer by introducing the protein E47, which can reprogram cancer cells back to their original state. This breakthrough offers new therapeutic possibilities and may lead to improved patient outcomes.
The American Association for Cancer Research (AACR) and Pancreatic Cancer Action Network have awarded $27 million in research grants to support innovative projects targeting pancreatic cancer. The grants aim to improve treatment and diagnosis of the deadly disease, which has the lowest survival rate among major cancers.
Researchers at Mayo Clinic have developed a profile to identify patients most at risk of developing pancreatic cancer. The study analyzed data from 1,126 patients and found that factors such as history of smoking, obesity, jaundice, and cyst size on imaging scans are associated with high risk.
Researchers at UT Southwestern Medical Center have identified a wealth of genetic diversity in pancreatic cancer, including multiple mutated genes that were previously unknown. The study also revealed potential diagnostic biomarkers and defined cases where certain drugs are selectively effective against specific mutations.
A magnetic resonance imaging (MRI)-based screening program identified pancreatic lesions in 40% of high-risk patients, with 5 requiring surgery. The study suggests that MRI can detect cancer or premalignant lesions with good accuracy, reducing costs and increasing availability compared to more aggressive methods.
Researchers at TGen are using zebrafish to accelerate investigations of pancreatic cancer, with the goal of finding therapeutics that can slow down and reverse tumor growth. The study is funded by the Seena Magowitz Foundation and aims to understand how pancreatic cancer invades local tissue and spreads to other organs.
Many cancers, including pancreatic cancer, enslave and deform mitochondria to create an environment conducive to tumor growth. Researchers found that blocking this process may lead to the growth of tumors.
Dr. Elizabeth Jaffee receives the AACR-Joseph H. Burchenal Award for her pioneering contributions to immunotherapies for breast and pancreatic cancers, leading to improved treatments and patient outcomes. Her work also focuses on establishing biomarkers of tumor microenvironment reprogramming.
Scientists at UTHealth received grants to identify new compounds that may treat lethal cancers by targeting K-Ras protein mutations. The research aims to develop anti-KRas drugs to improve treatment outcomes for millions suffering from these cancers.
Researchers found that a secreted immune protein called interleukin(IL)-17B promotes pancreatic cancer growth and metastasis. Treating tumor-bearing mice with an IL-17B inhibitor halted tumor growth and spread, resulting in increased survival.
Researchers at Indiana University identified a unique gene signature in pancreatic cancer patients who can benefit from targeted therapies cutting off the growth pathways fed by abnormal blood vessels. This finding suggests that these patients may benefit from precision medicine approaches.
A study of 100 pancreatic cancer genomes identifies four subtypes, including 'stable', 'locally rearranged', 'scattered', and 'unstable' genomes. The analysis suggests that patients with 'unstable' genomes respond well to platinum-based drugs and PARP inhibitors, offering a promising lead for personalized treatment.
A new TGen study finds targeting stroma surrounding cancer cells can improve treatments and extend patient survival in pancreatic cancer patients. High levels of stroma correlate with poor patient survival, with median survival rates ranging from 9-24 months depending on hyaluronan and collagen levels.
Researchers at Mayo Clinic and the University of Oslo have identified a molecule that transforms normal pancreatic cells into duct-like structures, which can become cancerous. Inhibiting this gene, PKD1, may halt progression and spread of pancreatic cancer.
Researchers at UNC Chapel Hill have developed a device that can deliver chemotherapy drugs directly into tumor tissue, allowing for potential life-saving surgeries and increased life expectancy. The device uses electric fields to target poorly vascularized tumors, which are difficult to treat with standard IV chemotherapy drugs.
A new course of action prescribing chemotherapy based on genetic research has led to a Phoenix resident being diagnosed with no detectable tumors after Stage 4 pancreatic cancer treatment. The patient benefited from a cutting-edge clinical trial and is now part of a follow-up study testing the effectiveness of a maintenance therapy.
Researchers at Moffitt Cancer Center discovered six microRNAs that can distinguish between high-risk and low-risk pancreatic lesions, offering a promising biomarker for early detection. This finding may lead to the development of a microRNA-based blood test to aid in predicting disease severity and foster new prevention strategies.
Fox Chase researchers discovered that pancreatic cancer cells sidestep chemotherapy by hijacking the vitamin D receptor, a key mechanism driving chemotherapeutic effectiveness against pancreatic cancer. The findings raise hopes for developing new treatments that can selectively kill cancer cells while leaving healthy cells unharmed.
Defects in extrusion, a process that helps cells die when overcrowded, may be a common hallmark of invasive tumor types. FAK inhibitors rescued cell death rates to normal and eliminated large cell masses.
Scientists have developed a breakthrough culturing system for human liver stem cells and pancreatic cancer stem cells, allowing for the growth of mini-organisms in the lab. This technology has the potential to revolutionize liver transplantation and aid in the fight against pancreatic cancer, with applications in personalized medicine.
A new study reveals that a specific gene, ATDC, plays a key role in the development of pancreatic cancer by promoting tumor growth and spread. The study found that patients with early-stage pancreatic cancer have a survival rate of only 30 percent.
Researchers at Scripps Research Institute discover a promising new treatment for aggressive breast and pancreatic cancers, using a synthetic compound called SR1848. The compound targets the LRH-1 protein, which is involved in hormone synthesis and cholesterol metabolism.